Loading
companiesCompany
Bio-Thera Solutions
Bio-Thera Solutions is a China-based pharmaceutical company running 3 late-stage cancer trials of BAT8008, BAT1308 and BAT8010 in cervical cancer.
Overview
Bio-Thera Solutions, based in Guangzhou, China, is a pharmaceutical company. Bio-Thera Solutions is a Guangzhou-based biopharmaceutical company that develops and markets antibody therapeutics, including approved biosimilars and pipeline candidates for cancer and autoimmune disease. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing BAT8008, BAT1308, BAT8010 and BAT1006 in cervical cancer. The largest, NCT06123884 (BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer), plans to enrol 526 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Guangzhou, CN
Scorecard
All companies#110of 1244 companies, score 48
- approved products +6
- targets +2
- modalities +2
- regions +8
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 1 targets, 2,405 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
Bevacizumab is a humanised antibody that soaks up VEGF-A, the signal tumours use to grow new blood vessels. Approved in 2004, it partners chemotherapy in colorectal, ovarian, cervical, lung, kidney and liver cancer and glioblastoma, and adds to trifluridine/tipiracil in late-line bowel cancer; hypertension, protein in the urine and bleeding are its characteristic side effects.
cancers
drugs
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
trials
A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid TumorsA Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic TumorsBAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer